|
19 |
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics |
알테오젠 |
2026-03-26 |
|
18 |
GSK Partnership Featured in Fierce Pharma and BioSpace |
Alteogen |
2026-01-21 |
|
17 |
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology |
Alteogen |
2026-01-20 |
|
16 |
44th Annual J.P. Morgan Healthcare Conference Presentation |
Alteogen |
2026-01-16 |
|
15 |
Alteogen CEO Interview Featured in Scrip Citeline |
Alteogen |
2026-01-06 |
|
14 |
Alteogen to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Alteogen |
2025-12-10 |
|
13 |
Alteogen Selects Lead Underwriter for KOSPI Transfer Listing |
Alteogen |
2025-09-29 |
|
12 |
Alteogen Files PCT Patent Application for ADC Subcutaneous Formulation Technology |
Alteogen |
2025-09-26 |
|
11 |
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9) |
Alteogen |
2025-09-17 |
|
10 |
Alteogen's CEO Soon Jae Park Interview Article (The Korea Economic Daily) |
Alteogen |
2025-08-19 |
